Woodline Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Woodline Partners’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,335,681	Closed	-$1.25M	–	1072
2024 Q4	$1.25M	Buy	2,335,681 +1,071,410	+85%	+$746K	0.01%	724
2024 Q3	$2.23M	Sell	1,264,271 -2,715,334	-68%	-$3.79M	0.02%	467
2024 Q2	$4.66M	Buy	3,979,605 +2,792,824	+235%	+$6.99M	0.04%	347
2024 Q1	$10.7M	Buy	1,186,781 +386,781	+48%	+$3.76M	0.1%	253
2023 Q4	$8.7M	Buy	800,000 +168,480	+27%	+$1.26M	0.09%	245
2023 Q3	$5.08M	Sell	631,520 -168,480	-21%	-$1.4M	0.06%	308
2023 Q2	$8.69M	Sell	800,000 -797,411	-50%	-$6.83M	0.1%	220
2023 Q1	$11M	Buy	1,597,411 +26,019	+2%	+$163K	0.15%	183
2022 Q4	$6.25M	Buy	1,571,392 +203,269	+15%	+$999K	0.08%	283
2022 Q3	$9.1M	Buy	+1,368,123	New	+$8.42M	0.13%	213

Woodline Partners's MRNS Position: Q1 2025 in Review

Woodline Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 2,335,681 shares — an estimated $1.25M sold.

Woodline Partners first reported a position in MRNS in Q3 2022 and held it in 10 quarters. The position peaked at $11M in Q1 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

Woodline Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 2,335,681 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $1.25M.
Woodline Partners first reported a position in Marinus Pharmaceuticals, Inc in Q3 2022 and held it in 10 quarters.
Woodline Partners's Marinus Pharmaceuticals, Inc position peaked at $11M in Q1 2023.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.